The  	The  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
iron  	iron  	 NN	O
deficiency  	deficiency  	 NN	O
in  	in  	 IN	O
menometrorrhagia  	menometrorrhagia  	 JJ	B-NP
Iron-deficiency  	Iron-deficiency  	 JJ	I-NP
anaemia 	anaemia 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
condition  	condition  	 NN	O
in  	in  	 IN	O
which  	which  	 WDT	O
anaemia  	anaemia  	 RB	O
occurs  	occurs  	 VBZ	O
due  	due  	 JJ	O
to  	to  	 TO	O
a  	a  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
iron 	iron 	 NN	B-NP
,  	,  	 ,	O
develops  	develops  	 VBZ	O
when  	when  	 WRB	O
the  	the  	 DT	O
amount  	amount  	 NN	O
of  	of  	 IN	O
available  	available  	 JJ	O
iron  	iron  	 NN	B-NP
is  	is  	 VBZ	O
insufficient  	insufficient  	 JJ	O
to  	to  	 TO	O
support  	support  	 VB	O
normal  	normal  	 JJ	B-NP
red  	red  	 JJ	I-NP
blood  	blood  	 NN	I-NP
cell  	cell  	 NN	I-NP
production 	production 	 NN	I-NP
.  	.  	 .	O
Iron  	Iron  	 NNP	O
deficiency  	deficiency  	 NN	O
and  	and  	 CC	O
iron-deficiency  	iron-deficiency  	 JJ	B-NP
anaemia 	anaemia 	 NN	I-NP
,  	,  	 ,	O
very  	very  	 RB	O
prevalent  	prevalent  	 JJ	O
conditions  	conditions  	 NNS	O
in  	in  	 IN	O
premenopausal  	premenopausal  	 JJ	B-NP
women 	women 	 NNS	I-NP
,  	,  	 ,	O
are  	are  	 VBP	O
often  	often  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
menometrorrhagia  	menometrorrhagia  	 NNS	B-NP
( 	( 	 -LRB-	O
present  	present  	 JJ	O
in  	in  	 IN	O
more  	more  	 JJR	O
than  	than  	 IN	O
two-thirds  	two-thirds  	 NNS	B-NP
of  	of  	 IN	O
cases  	cases  	 NNS	O
of  	of  	 IN	O
iron-deficiency  	iron-deficiency  	 JJ	B-NP
anaemia  	anaemia  	 NN	I-NP
in  	in  	 IN	O
premenopausal  	premenopausal  	 JJ	B-NP
women 	women 	 NNS	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Appropriate  	Appropriate  	 JJ	B-NP
identification  	identification  	 NN	I-NP
and  	and  	 CC	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
iron  	iron  	 NN	O
deficiency  	deficiency  	 NN	O
is  	is  	 VBZ	O
imperative  	imperative  	 VBN	O
as  	as  	 IN	O
iron  	iron  	 NN	O
deficiency  	deficiency  	 NN	O
can  	can  	 MD	O
induce  	induce  	 VB	O
important  	important  	 JJ	O
specific  	specific  	 JJ	O
clinical  	clinical  	 JJ	B-NP
manifestations  	manifestations  	 NNS	I-NP
( 	( 	 -LRB-	O
including  	including  	 VBG	B-NP
fatigue 	fatigue 	 NN	I-NP
,  	,  	 ,	O
atrophic  	atrophic  	 JJ	B-NP
changes  	changes  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
epithelium 	epithelium 	 NN	B-NP
,  	,  	 ,	O
oral  	oral  	 JJ	B-NP
lesions 	lesions 	 NNS	I-NP
,  	,  	 ,	O
dysphagia 	dysphagia 	 NN	B-NP
,  	,  	 ,	O
nail  	nail  	 JJ	O
lesions 	lesions 	 NNS	O
,  	,  	 ,	O
reduced  	reduced  	 VBD	O
immune  	immune  	 JJ	O
response 	response 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Iron  	Iron  	 NNP	B-NP
supplementation  	supplementation  	 NN	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
strategy  	strategy  	 NN	O
used  	used  	 VBN	O
to  	to  	 TO	O
control  	control  	 VB	O
iron  	iron  	 NN	O
deficiency 	deficiency 	 NN	O
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
World  	World  	 NNP	B-NP
Health  	Health  	 NNP	I-NP
Organisation  	Organisation  	 NNP	I-NP
recommendations 	recommendations 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
most  	most  	 RBS	O
appropriate  	appropriate  	 JJ	O
treatment  	treatment  	 NN	O
is  	is  	 VBZ	O
with  	with  	 IN	O
an  	an  	 DT	O
oral  	oral  	 JJ	B-NP
ferrous  	ferrous  	 JJ	I-NP
salt  	salt  	 NN	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
prolonged-release  	prolonged-release  	 JJ	B-NP
tablet  	tablet  	 JJ	I-NP
form 	form 	 NN	I-NP
,  	,  	 ,	O
to  	to  	 TO	O
provide  	provide  	 VB	O
a  	a  	 DT	O
dose  	dose  	 NN	O
of  	of  	 IN	O
elemental  	elemental  	 JJ	B-NP
iron  	iron  	 NN	I-NP
equivalent  	equivalent  	 NN	I-NP
to  	to  	 TO	O
60  	60  	 CD	O
mg  	mg  	 NN	B-NP
per  	per  	 IN	O
intake 	intake 	 NN	O
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
range  	range  	 NN	O
of  	of  	 IN	O
60  	60  	 CD	O
and  	and  	 CC	O
120  	120  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
day  	day  	 NN	I-NP
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
severity  	severity  	 NN	O
of  	of  	 IN	O
iron-deficiency  	iron-deficiency  	 JJ	B-NP
anaemia 	anaemia 	 NN	I-NP
.  	.  	 .	O
When  	When  	 WRB	O
haemoglobin  	haemoglobin  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
have  	have  	 VBP	O
returned  	returned  	 VBN	O
to  	to  	 TO	O
normal 	normal 	 JJ	O
,  	,  	 ,	O
treatment  	treatment  	 NN	O
should  	should  	 MD	O
continue  	continue  	 VB	O
for  	for  	 IN	O
about  	about  	 IN	O
3  	3  	 CD	O
months  	months  	 NNS	O
to  	to  	 TO	O
fill  	fill  	 VB	O
iron  	iron  	 NN	B-NP
stores 	stores 	 NNS	I-NP
.  	.  	 .	O
An  	An  	 DT	O
extended-release  	extended-release  	 JJ	B-NP
formulation  	formulation  	 NN	I-NP
of  	of  	 IN	I-NP
ferrous  	ferrous  	 JJ	I-NP
sulphate  	sulphate  	 NN	I-NP
with  	with  	 IN	O
mucoproteose  	mucoproteose  	 NN	B-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
gastrointestinal  	gastrointestinal  	 JJ	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
other  	other  	 JJ	O
ferrous  	ferrous  	 NN	B-NP
and  	and  	 CC	O
ferric  	ferric  	 JJ	B-NP
salts 	salts 	 NN	I-NP
.  	.  	 .	O
